Senate chance to improve 'Cures,' but don't expect soon
This article was originally published in Scrip
Executive Summary
Legislation the House adopted earlier this month – the 21st Century Cures Act – was a good start towards modernizing the US medical product development system, but the Senate needs to include other measures in its bill aimed at keeping the nation competitive and protecting innovation from overly burdensome regulations, the Bipartisan Policy Center (BPC), a Washington think tank, said in a new report.